As the circle of doctors ordering drug testing expands, labs find themselves more involved in advisory and interpretive roles that go beyond running assays.
Researchers developing the gene expression-based test say it could bring objectivity to a subjective diagnosis and result in more targeted treatments.
A deep analysis of data from drug tests performed at Quest over the past six years has helped the company identify which drug tests are needed by clinicians.
Molecular Testing Labs allegedly made payments to labs in exchange for Medicare and Tricare referrals between August 2014 and July 2015.
The Tulsa, Oklahoma-based lab, which received its CLIA license in August, will run samples reimbursed by Medicare and state Medicaid agencies only.
The lab will test samples reimbursed only by the federal government. Attis expects it will test a baseline of 3,000 toxicology samples per month by the end of 2018.
The US Attorney's Office, Western District of Pennsylvania alleged the doctors received improper payments for referrals from drug testing lab Universal Oral Fluid Laboratories.
In addition to lower reimbursements, Ameritox also faced a fraudulent claims lawsuit from Humana.
The OIG recommends that CMS direct Medicare contractors to recover the improper payments from providers and strengthen system edits to prevent further improper payments.
By dropping the cutoff value in urine immunoassay testing to 20 from 100, the researchers reduced the false-negative rate to 2 percent from 47 percent.